Evaluation of patients with implantable cardioverter-defibrillator in a Latin American tertiary center
Anna Terra França MD, MSc
Cardiology Service, Hospital das Clínicas da Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil
Search for more papers by this authorLarissa Natany Almeida Martins MSc
Departamento de estatística da Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil
Search for more papers by this authorDerick Matheus de Oliveira MSc
Departamento de Ciência da Computação da Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil
Search for more papers by this authorFábio Morato de Castilho MD, MSc, PhD
Cardiology Service, Hospital das Clínicas da Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil
Search for more papers by this authorBeatriz Castello Branco MBBS
Interdisciplinary Laboratory of Medical Investigation, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil
Search for more papers by this authorBruno Wilnes MBBS
Interdisciplinary Laboratory of Medical Investigation, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil
Search for more papers by this authorCorresponding Author
Antônio Luiz P. Ribeiro MD, PhD
Cardiology Service, Hospital das Clínicas da Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil
Department of Internal Medicine, Faculdade de Medicina, Belo Horizonte, Brazil
Correspondence Antônio Luiz P. Ribeiro, MD, PhD, Centro de Telessaúde—Hospital das Clínicas—UFMG, Av. Professor Alfredo Balena, 110, 1° Andar, Ala Sul, Sala 107 30130-100, Belo Horizonte, MG, Brazil.
Email: [email protected]
Search for more papers by this authorAndré Assis Lopes do Carmo MD, MSc, PhD
Cardiology Service, Hospital das Clínicas da Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil
Search for more papers by this authorAnna Terra França MD, MSc
Cardiology Service, Hospital das Clínicas da Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil
Search for more papers by this authorLarissa Natany Almeida Martins MSc
Departamento de estatística da Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil
Search for more papers by this authorDerick Matheus de Oliveira MSc
Departamento de Ciência da Computação da Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil
Search for more papers by this authorFábio Morato de Castilho MD, MSc, PhD
Cardiology Service, Hospital das Clínicas da Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil
Search for more papers by this authorBeatriz Castello Branco MBBS
Interdisciplinary Laboratory of Medical Investigation, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil
Search for more papers by this authorBruno Wilnes MBBS
Interdisciplinary Laboratory of Medical Investigation, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil
Search for more papers by this authorCorresponding Author
Antônio Luiz P. Ribeiro MD, PhD
Cardiology Service, Hospital das Clínicas da Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil
Department of Internal Medicine, Faculdade de Medicina, Belo Horizonte, Brazil
Correspondence Antônio Luiz P. Ribeiro, MD, PhD, Centro de Telessaúde—Hospital das Clínicas—UFMG, Av. Professor Alfredo Balena, 110, 1° Andar, Ala Sul, Sala 107 30130-100, Belo Horizonte, MG, Brazil.
Email: [email protected]
Search for more papers by this authorAndré Assis Lopes do Carmo MD, MSc, PhD
Cardiology Service, Hospital das Clínicas da Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil
Search for more papers by this authorDisclosures: None.
Abstract
Introduction
Despite advancements in implantable cardioverter-defibrillator (ICD) technology, sudden cardiac death (SCD) remains a persistent public health concern. Chagas disease (ChD), prevalent in Brazil, is associated with increased ventricular tachycardia (VT) and ventricular fibrillation (VF) events and SCD compared to other cardiomyopathies.
Methods
This retrospective observational study included patients who received ICDs between October 2007 and December 2018. The study aims to assess whether mortality and VT/VF events decreased in patients who received ICDs during different time periods (2007–2010, 2011–2014, and 2015–2018). Additionally, it seeks to compare the prognosis of ChD patients with non-ChD patients. Time periods were chosen based on the establishment of the Arrhythmia Service in 2011. The primary outcome was overall mortality, assessed across the entire sample and the three periods. Secondary outcomes included VT/VF events and the combined outcome of death or VT/VF.
Results
Of the 885 patients included, 31% had ChD. Among them, 28% died, 14% had VT/VF events, and 37% experienced death and/or VT/VF. Analysis revealed that period 3 (2015–2018) was associated with better death-free survival (p = .007). ChD was the only variable associated with a higher rate of VT/VF events (p < .001) and the combined outcome (p = .009).
Conclusion
Mortality and combined outcome rates decreased gradually for ICD patients during the periods 2011–2014 and 2015–2018 compared to the initial period (2007–2010). ChD was associated with higher VT/VF events in ICD patients, only in the first two periods.
Open Research
DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available from the corresponding author upon reasonable request.
REFERENCES
- 1Tepper D. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomised intervention trial in congestive heart failure (MERIT-HF). Congestive Heart Failure. 1999; 353(9169): 2001-2007. doi:10.1016/S0140-6736(99)04440-2
- 2Domanski MJ, Exner DV, Borkowf CB, Geller NL, Rosenberg Y, Pfeffer MA. Effect of angiotensin converting enzyme inhibition on sudden cardiac death in patients following acute myocardial infarction. J Am Coll Cardiol. 1999; 33(3): 598-604. doi:10.1016/S0735-1097(98)00609-3
- 3Pfeffer MA, McMurray JJV, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003; 349(20): 1893-1906. doi:10.1056/NEJMoa032292
- 4McMurray JJV, Packer M, Desai AS, et al. Angiotensin–neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014; 371(11): 993-1004. doi:10.1056/NEJMoa1409077
- 5Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999; 341(10): 709-717. doi:10.1056/NEJM199909023411001
- 6Mitchell LB, Powell JL, Gillis AM, Kehl V, Hallstrom AP. Are lipid-lowering drugs also antiarrhythmic drugs. J Am Coll Cardiol. 2003; 42(1): 81-87. doi:10.1016/S0735-1097(03)00498-4
- 7Fernandes GC, Fernandes A, Cardoso R, et al. Association of SGLT2 inhibitors with arrhythmias and sudden cardiac death in patients with type 2 diabetes or heart failure: a meta-analysis of 34 randomized controlled trials. Heart Rhythm. 2021; 18(7): 1098-1105. doi:10.1016/j.hrthm.2021.03.028
- 8Shuvy M, Qiu F, Lau G, et al. Temporal trends in sudden cardiac death in Ontario, Canada. Resuscitation. 2019; 136: 1-7. doi:10.1016/j.resuscitation.2019.01.010
- 9Connolly S. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. Eur Heart J. 2000; 21(24): 2071-2078. doi:10.1053/euhj.2000.2476
- 10Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter–defibrillator for congestive heart failure. N Engl J Med. 2005; 352(3): 225-237. doi:10.1056/NEJMoa043399
- 11Desai AS, Fang JC, Maisel WH, Baughman KL. Implantable defibrillators for the prevention of mortality in patients with nonischemic cardiomyopathy. JAMA. 2004; 292(23):2874. doi:10.1001/jama.292.23.2874
- 12Cleland JGF, Daubert JC, Erdmann E, et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med. 2005; 352(15): 1539-1549. doi:10.1056/NEJMoa050496
- 13Oliveira GMM, Brant LCC, Polanczyk CA, et al. Estatística cardiovascular—Brasil 2020. Arq Bras Cardiol. 2020; 115(3): 308-439. doi:10.36660/abc.20200812
- 14Braggion-Santos MF, Volpe GJ, Pazin-Filho A, Maciel BC, Marin-Neto JA, Schmidt A. Sudden cardiac death in Brazil: a community-based autopsy series (2006-2010). Arq Bras Cardiol. 2015; 104(2): 120-127. doi:10.5935/abc.20140178
- 15Rassi Jr. A, Rassi SG, Rassi A. Sudden death in Chagas' disease. Arq Bras Cardiol. 2001; 76(1): 86-96. doi:10.1590/S0066-782X2001000100008
10.1590/S0066-782X2001000100008 Google Scholar
- 16Nadruz W, Gioli-Pereira L, Bernardez-Pereira S, et al. Temporal trends in the contribution of Chagas cardiomyopathy to mortality among patients with heart failure. Heart. 2018; 104(18): 1522-1528. doi:10.1136/heartjnl-2017-312869
- 17Carmo AAL, de Sousa MR, Agudelo JF, et al. Implantable cardioverter-defibrillator in Chagas heart disease: a systematic review and meta-analysis of observational studies. Int J Cardiol. 2018; 267(2018): 88-93. doi:10.1016/j.ijcard.2018.05.091
- 18Barbosa MPT, da Costa Rocha MO, de Oliveira AB, Lombardi F, Ribeiro ALP. Efficacy and safety of implantable cardioverter-defibrillators in patients with Chagas disease. EP Europace. 2013; 15(7): 957-962. doi:10.1093/europace/eut011
- 19Filho MM, De Siqueira SF, Moreira H, et al. Probability of occurrence of life-threatening ventricular arrhythmias in chagas' disease versus non-Chagas' disease. probability of occurrence of life-threatening ventricular arrhythmias in Chagas' disease versus non-chagas' disease. Pacing Clin Electrophysiol. 2000; 23(11P2): 1944-1946. doi:10.1111/j.1540-8159.2000.tb07058.x
- 20Rabinovich R, Muratore C, Iglesias R, et al. Time to first shock in implantable cardioverter defibrillator (ICD) patients with Chagas cardiomyopathy. Pacing Clin Electrophysiol. 1999; 22(1): 202-205. doi:10.1111/j.1540-8159.1999.tb00333.x
- 21Connolly SJ, Dorian P, Roberts RS, et al. Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC study: a randomized trial. JAMA. 2006; 295(2): 165-171. doi:10.1001/jama.295.2.165
- 22Schron EB, Exner DV, Yao Q, et al. Quality of life in the antiarrhythmics versus implantable defibrillators trial. Circulation. 2002; 105(5): 589-594. doi:10.1161/hc0502.103330
- 23Larsen GK, Evans J, Lambert WE, Chen Y, Raitt MH. Shocks burden and increased mortality in implantable cardioverter-defibrillator patients. Heart Rhythm. 2011; 8(12): 1881-1886. doi:10.1016/j.hrthm.2011.07.036
- 24Villacastı́n J, Almendral J, Arenal A, et al. Incidence and clinical significance of multiple consecutive, appropriate, high-energy discharges in patients with implanted cardioverter-defibrillators. Circulation. 1996; 93(4): 753-762. doi:10.1161/01.CIR.93.4.753
- 25Ha AH, Ham I, Nair GM, et al. Implantable cardioverter-defibrillator shock prevention does not reduce mortality: a systemic review. Heart Rhythm. 2012; 9(12): 2068-2074. doi:10.1016/j.hrthm.2012.08.032
- 26Sapp JL, Wells GA, Parkash R, et al. Ventricular tachycardia ablation versus escalation of antiarrhythmic drugs. N Engl J Med. 2016; 375(2): 111-121. doi:10.1056/NEJMoa1513614
- 27Della Bella P, Baratto F, Vergara P, et al. Does timing of ventricular tachycardia ablation affect prognosis in patients with an implantable cardioverter defibrillator? results from the multicenter randomized PARTITA trial. Circulation. 2022; 145(25): 1829-1838. doi:10.1161/CIRCULATIONAHA.122.059598
- 28Arenal Á, Ávila P, Jiménez-Candil J, et al. Substrate ablation vs antiarrhythmic drug therapy for symptomatic ventricular tachycardia. J Am Coll Cardiol. 2022; 79(15): 1441-1453. doi:10.1016/j.jacc.2022.01.050
- 29Romero J, Velasco A, Pisani CF, et al. Advanced therapies for ventricular arrhythmias in patients with chagasic cardiomyopathy. J Am Coll Cardiol. 2021; 77(9): 1225-1242. doi:10.1016/j.jacc.2020.12.056
- 30Wang Y, Zhu H, Hou X, et al. Randomized trial of left bundle branch vs biventricular pacing for cardiac resynchronization therapy. J Am Coll Cardiol. 2022; 80(13): 1205-1216. doi:10.1016/j.jacc.2022.07.019
- 31Carmo AAL, Miranda RC, Lacerda-Filho A, Ribeiro ALP. Laparoscopic guided epicardial access. Heart Rhythm. 2015; 12(2): 461-462. doi:10.1016/j.hrthm.2014.11.039
- 32Tan VH, Wilton SB, Kuriachan V, Sumner GL, Exner DV. Impact of programming strategies aimed at reducing nonessential implantable cardioverter defibrillator therapies on mortality. Circ Arrhythm Electrophysiol. 2014; 7(1): 164-170. doi:10.1161/CIRCEP.113.001217
- 33Vaidya VR, Asirvatham R, Kowlgi GN, et al. Trends in cardiovascular implantable electronic device insertion between 1988 and 2018 in olmsted county. JACC Clin Electrophysiol. 2022; 8(1): 88-100. doi:10.1016/j.jacep.2021.06.006
- 34Vieira de Melo RM, de Azevedo DFC, Lira YM, Cardoso de Oliveira NF, Passos LCS. Chagas disease is associated with a worse prognosis at 1-year follow-up after implantable cardioverter-defibrillator for secondary prevention in heart failure patients. J Cardiovasc Electrophysiol. 2019; 30(11): 2448-2452. doi:10.1111/jce.14164
- 35Cardinalli-Neto A, Bestetti RB, Cordeiro JA, Rodrigues VC. Predictors of all-cause mortality for patients with chronic Chagas' heart disease receiving implantable cardioverter defibrillator therapy. J Cardiovasc Electrophysiol. 2007; 18(12): 1236-1240. doi:10.1111/j.1540-8167.2007.00954.x
- 36Rassi A. Implantable cardioverter-defibrillators in patients with Chagas heart disease: misperceptions, many questions and the urgent need for a randomized clinical trial. J Cardiovasc Electrophysiol. 2007; 18(12): 1241-1243. doi:10.1111/j.1540-8167.2007.01011.x
- 37Rassi A, Rassi A. Another disappointing result with implantable cardioverter-defibrillator therapy in patients with Chagas disease. Europace. 2013; 15(9): 1383. doi:10.1093/europace/eut092
- 38Migowski A, Chaves RBM, Coeli CM, et al. Acurácia do relacionamento probabilístico na avaliação da alta complexidade em cardiologia. Rev Saude Publica. 2011; 45(2): 269-275. doi:10.1590/S0034-89102011005000012
Citing Literature
